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Abstract: Only palliative therapeutic options exist for the treatment of Alzheimer’s Disease; no new
successful drug candidates have been developed in over 15 years. The widely used clinical antico-
agulant heparin has been reported to exert beneficial effects through multiple pathophysiological
pathways involved in the aetiology of Alzheimer’s Disease, for example, amyloid peptide production
and clearance, tau phosphorylation, inflammation and oxidative stress. Despite the therapeutic po-
tential of heparin as a multi-target drug for Alzheimer’s disease, the repurposing of pharmaceutical
heparin is proscribed owing to the potent anticoagulant activity of this drug. Here, a heterogenous
non-anticoagulant glycosaminoglycan extract, obtained from the shrimp Litopenaeus vannamei, was
found to inhibit the key neuronal β-secretase, BACE1, displaying a more favorable therapeutic ratio
compared to pharmaceutical heparin when anticoagulant activity is considered.
Keywords: Alzheimer’s disease; amyloid-β; BACE1; β-secretase; glycosaminoglycan; chondroitin
sulfate; heparin; heparan sulphate; Litopenaeus vannamei
1. Introduction
Alzheimer’s disease (AD) is a progressive, irreversible, neurodegenerative disorder
characterized by the formation of extracellular amyloid plaques and intracellular neurofib-
rillary tangles (NFTs) within the brain. Despite many hundreds of clinical trials for novel
treatment options against AD, none have delivered a viable pharmaceutical since 2003 [1]
and currently only solely palliative drugs are licensed for use [2]. Hence, there is an urgent
need for new therapeutic agents that can interact with the underpinning mechanisms
of AD.
Amyloid deposits within the cerebral cortex are considered to be a consequence of the
production of amyloidogenic amyloid precursor protein (APP) fragments generated by the
sequential proteolytic processing of the type 1 transmembrane protein APP. Fragmentation
of APP into amyloidogenic peptides occurs through the action of several proteases begin-
ning with cleavage by the primary neuronal β-secretase, BACE-1, which yields a soluble
N-terminal fragment (sAPPβ) and a membrane located C-terminus fragment (CTF-99). The
CTF-99 fragment is further cleaved by γ-secretase, yielding Aβ peptides (predominantly
Aβ 40–42) [3–5]. Aggregation of Aβ peptides into toxic species is thought to initiate other
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neuropathies such as NFTs, inflammation and oxidative stress, which together result in
neuronal death, brain atrophy and AD [2]. Inhibition of the key protease that leads to the
generation of Aβ fragments, BACE1, has therefore emerged as a key drug target in the
development of novel AD pharmaceuticals [6].
The glycosaminoglycan (GAG) heparan sulphate (HS) has previously been identified
as the physiological regulator of BACE-1 by Scholefield et al. (2003) [7] and the extant
pharmaceutical anticoagulant heparin, a highly sulphated variant of HS, inhibits BACE-1
in vitro [7]. Heparin binding has been proposed to occur within a region of BACE-1 that
prevents substrate access to the active site, and to act via a mechanism that differs from
conventional small molecule inhibitors [7–9]. Glycosaminoglycan-derived oligosaccharides
have also been shown to cross the blood–brain barrier [10], whilst co-localizing with and
inhibiting, BACE-1 [7,11].
In addition to BACE-1 inhibition, exogenous heparin also exerts manifold beneficial
effects against other AD related neuropathies. Examples include preventing Aβ proin-
flammatory activity, acting as a Cu2+ and Zn2+ chelator, decreasing NFT formation, and
reducing apolipoprotein E associated toxicity [12,13]. Indicating that heparin and related
polysaccharides have the potential to act as multi-target drugs; an approach which is consid-
ered favourable for AD drug development [14]. Mouse models treated with low-molecular
weight heparin (LWMH) derivatives have also displayed decreased Aβ deposition and
improved cognitive functions [15,16], providing further promise for the application of hep-
arin as a treatment for AD. Despite this, the repurposing of mammalian-derived heparin
and low molecular weight oligosaccharides as a treatment for AD is largely prohibited by
the likely side effect of anticoagulation.
The GAGs HS and heparin are composed of a repeating disaccharide backbone of
D-glucuronic acid (GlcA) linked β(1→4) to D-glucosamine. The repeating disaccharide
backbone can possess variable levels of modifications, including epimerisation of β D-GlcA
to α L-iduronic acid (IdoA) and sulphation at defined positions alone the polysaccharide
chain. In addition to HS/heparin, the GAG family also contains chondroitin sulphate (CS),
dermatan sulphate (DS), hyaluronic acid (HA) and keratan sulphate (KS). Chondroitin
sulphate and DS both comprise a uronic acid linked β (1→3) to N-acetyl D-galactosamine,
with the uronic acid residue being β D-GlcA or α L-IdoA, respectively. Chondroitin
sulphate and DS can also contain varying levels of sulphate modifications [17]. The fine
structure imparted by these modifications modulate protein-GAG interactions and bestow
functional activities, such as BACE-1 inhibition, upon these polysaccharides [11,18].
In contrast to mammalian-derived GAGs, marine organisms provide a rich and diverse
source of GAGs that possess increased structural diversity [9,19–26]. Glycosaminoglycans
have been identified belonging to phyla such as Cnidaria, Crustacea, Tunicata and Mollusca,
that are structurally related to their mammalian-derived counterparts. Regarding the con-
stituent disaccharide units, however, they differ in their detailed disaccharide composition
according to the species from which they have been extracted [27,28]. The exploration of
the structural diversity offered by marine derived GAG offers increased sequence space for
the discovery of GAGs with favourable bioactivities and reduced off-target effects such as
anticoagulant activity [17,19,22,29]. Marine derived GAGs are additionally advantageous
since they may be acquired from aquaculture waste, making their exploitation economically,
environmentally and socially appealing.
Previously, we have shown HS and CS extracts obtained from the marine organisms
Portunus pelagicus and Sardina pilchardus inhibit BACE1 [9,30]. These marine-derived GAGs
retain favourable inhibitory activities against BACE-1, when compared to mammalian-
derived heparin, whilst exhibiting diminished anticoagulation activity. Here, we report
a further GAG extract obtained from Litopenaeus vannamei, composed of a mixture of
chondroitin sulphate and heparan sulphate, that can inhibit BACE-1 and also displays
attenuated anticoagulant properties.
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2. Results
2.1. Isolation of Glycosaminoglycans from Litopenaeus vannamei
A crude glycosaminoglycan extract was obtained from defatted Litopenaeus vannamei
tissue by proteolytic digestion (Alcalase®; Novozymes, Krogshøjvej, Bagsvaerd, Denmark),
followed by capture and elution from strongly basic anion exchange resin (Amberlite®
IRA-900; Sigma-Aldrich, Dorset, UK), as previously described by Mycroft-West et al. (2019
and 2020) [9,30]. The crude GAG extract was further fractionated using DEAE-based, anion-
exchange chromatography employing a stepwise sodium chloride gradient for elution
(Figure 1). Fractions corresponding to elution at 0.8 M (fraction 4) and 1M (fraction 5) NaCl
accounted for ~43% and ~30% of the crude sample, respectively.
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utilised to investigate the electrophoretic mobility of L. vannamei F4 and F5 in comparison 
to GAG standards (Figure 2). Both fractions separated into two distinct bands correspond-
ing to HS and CS, suggesting that L. vannamei F4 and F5 are composed of a heterogenous 
mixture of GAGs. The major constituent of both fractions possessed similar electropho-
retic mobility to mammalian HS, migrating further than porcine heparin, but less than 
both CS and DS standards. A further minor band was also present in both fractions, mi-
grating at a slightly greater distance than mono- and disulphated CS standards (Figure 2). 
Figure 1. DEAE anion exchange chromatography purification of crude glycosaminoglycan from
L. vannamei. Fractions 1–6 (solid line) correspond to a stepwise NaCl elution with in-line monitoring
at 232 nm (dashed line).
The structural characteristics of L. vannamei fractions 4 and 5 (F4 and F5, respec-
tively) were subsequently characterised by several spectroscopic techniques that are widely
employed in the composition analysis of GAGs.
2.2. Characterisation of Extracted Glycosaminoglycans from Litopenaeus vannamei
2.2.1. Agarose-Based, Gel Electrophoresis
Agarose-based gel electrophoresis in 1,3-diaminopropane buffer (pH 9.0) was first
utilised to investigate the electrophoretic mobility of L. vannamei F4 and F5 in comparison to
GAG standards (Figure 2). Both fractions separated into two distinct bands corresponding
to HS and CS, suggesting th t L. vannamei F4 and F5 a e composed of a heterogenous
mixture of GAGs. The m jor constituent of both fractions possessed similar electrophoretic
mobility to mammalian HS, migrating further than porcine heparin, but less than both CS
and DS standards. A further minor band was also present in both fractions, migrating at a
slightly greater distance than mono- and disulphated CS standards (Figure 2).
2.2.2. Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy
As agarose gel electrophoresis revealed bands with migration distances corresponding
to HS and CS, within both fractions, ATR-FTIR spectroscopy was employed to elucidate the
GAG composition of L. vannamei F4 and F5. The ATR-FTIR spectra of L. vannamei F4 and F5
were compared to those of CS and HS as these were the major GAGs with corresponding
migrations observed by agarose gel electrophoresis (Figure 3). Both L. vannamei F4 and
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F5 contained spectral features representative of GAGs, with peaks corresponding to the
common motifs; S=O, symmetric carbonyl stretching and asymmetric stretching at 1230,
1430 and 1635 cm−1, respectively (Figure 3). The peak shoulder observed at 1559 cm−1,
which is present in all samples, has also previously been assigned to the amide II band
corresponding to coupled C-N vibrations of N-acetyl (amide) groups, a characteristic
structural feature.




Figure 2. Electrophoretic mobility of L. vannamei F4 (A) and F5 (B) and reference glycosaminogly-
cans; heparin, heparan sulphate (HS), dermatan sulphate (DS) and chondroitin sulphate A, C and 
D (CSA, CSC and CSD, respectively), M = mixture of CSA and heparin. 
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fore, the ATR-FTIR spectra of L. vannamei F4 and F5 were subjected to multivariate anal-
ysis, post-acquisition, with comparison to a library of known GAGs comprising 185 hep-
arins, 31 HS, 44 CSs and DSs, 11 HAs and 6 OSCSs, using principal component analysis 
(PCA). 
Comparison of PC1 and PC2, which covers > 70% of the total variance, indicates that 
both L. vannamei F4 and F5 locate within the region containing mammalian HS (Figure 4A 
and Figure 4B, respectively). Principal component 1, which covers 57% of the total vari-
ance, indicates that both L. vannamei F4 and F5 separate towards the region containing CS. 
This region has previously been identified with heparin samples containing CS contami-
nants [31]. The separation towards this region was more pronounced for L. vannamei F4 
than F5, suggesting a greater proportion of CS in F4 (Figure 4). 
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Figure 3. ATR-FTIR spectra of (A) L. vannamei F4 (red) and HS (black) (B) L. vannamei F4 (red) and
CS (black), (C) L. vannamei F5 (red) and HS (black) and (D) L. vannamei F5 (red) and CS (black); n = 5.
Notably, the ATR-FTIR spectra of HS exhibited a peak at 990 cm−1 with a peak
shoulder at 1025 cm−1. This was reversed in the CS ATR-FTIR spectra with the main
peak occurring at 1025 cm−1 and peak shoulder at 990 cm−1 (Figure 3). Bands in the
region of 1200–900 cm−1 have previ usly been assigned to th C-O-C lycosidic bond
stretches [31–34], therefo the differences observed between CS and HS in this reg on
could be attributed to differences in glycosidic bond linkages between these GAGs.
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L. vannamei F4 contained a split peak at 990 cm−1 and 1025 cm−1, whereas the peak
at 990 cm−1 was more prominent in L. vannamei F5, with a peak shoulder occurring at
1025 cm−1. This suggests that L. vannamei F5 contains a higher proportion of HS than
L. vannamei F4. There are also differences in the intensities of peaks at ~1450 cm−1 and
1600 cm−1, between HS and CS samples (Figure 3), with both L. vannamei F4 and F5 more
closely resembling HS in these regions. In addition, the peak shoulder at ~1370 cm−1,
present in both L. vannamei F4 and F5, has also been suggested as indicative of a HS/CS
mixture [31], further supporting the notion that both fractions are composed of a mixture
of these GAGs. An additional peak at ~1725 cm−1 was observed in both L. vannamei F4
and F5, but was absent in both HS and CS (Figure 3), suggesting that the L. vannamei GAG
extracts may contain rare structural features.
The differences between the spectra of HS, CS and L. vannamei F4 and F5 in the region
>3000 cm−1 (OH stretch region) are associated with changeable moisture levels introduced
during sample acquisition and not likely to result from underlying structural differences as
mentioned previously [31].
Owing to the complex nature of GAGs and the heterogeneity of sample preparations,
ATR-FTIR spectra of GAGs are often complex, with extensive signal overlap and therefore,
lack the spectral resolution of 2-dimensional (1H-13C) NMR; as a result, it is not currently
possible to provide complete assignment for the ATR-FTIR spectra of GAGs. Therefore,
the ATR-FTIR spectra of L. vannamei F4 and F5 were subjected to multivariate analysis,
post-acquisition, with comparison to a library of known GAGs comprising 185 heparins,
31 HS, 44 CSs and DSs, 11 HAs and 6 OSCSs, using principal component analysis (PCA).
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that both L. vannamei F4 and F5 locate within the region containing mammalian HS
(Figures 4A and 4B, respectively). Principal component 1, which covers 57% of the total
variance, indicates that both L. vannamei F4 and F5 separate towards the region containing
CS. This region has previously been identified with heparin samples containing CS con-
taminants [31]. The separation towards this region was more pronounced for L. vannamei
F4 than F5, suggesting a greater proportion of CS in F4 (Figure 4).
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Figure 4. Principal component analysis score plot for PC2 vs. PC1 from the ATR-FTIR spectra of
(A) L. vannamei F4 and (B) L. vannamei F5 against a bone fide GAG library. Heparin (black), HS
(dark blue), CS (orange), DS (magenta), HA (cyan), over-sulphated CS (light green) and L. vannamei
fractions (red).
2.2.3. Nuclear Magnetic Resonance
Proton and heteronuclear single-quantum correlation (HSQC) NMR spectroscopy
were employed to confirm the GAG composition of L. vannamei F4 and F5. Through their
characteristic chemical shift positions, 1H NMR can distinguish the major signals associated
with HS, as well as those that arise from galactosaminoglycans such as CS and DS. Signals
associated with the N-acetyl of CS (~2.02 ppm), DS (~2.07 ppm) and HS (~2.04 ppm) were
present in both L. vannamei F4 and F5 (Figure 5). The major N-acetyl signal in both fractions
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at 2.02 ppm suggest that the fractions contain a larger quantity of CS than indicated by
ATR-FTIR spectroscopy and agarose gel analysis. Owing to the heterogeneity of the sample
and resulting overlapping resonances in the 1H NMR spectra, further assignment was
preformed utilising 1H -13C HSQC NMR. The signals attributed to N-acetyl signals in the
1H-13C HSQC further indicated that L. vannamei F4 and F5 are composed of CS, HS and DS
(Figure 5, insert).




Figure 5. (A) 1H and (B) 1H-13C HSQC NMR spectra of L. vannamei F4, (C) 1H and (D) 1H-13C 
HSQC of L. vannamei F5. Major signals associated with CS and HS are indicated. Spectral integra-
tion was performed on the HSQC using labelled signals. Glucosamine, Glc; galactosamine, Gal; 
uronic acid, U; iduronic acid, I. 
2.2.4. Strong Anion-Exchange High Performance Liquid Chromatography Disaccharide 
Compositional Analysis 
Since NMR spectroscopy revealed that L. vannamei F4 and F5 contained a signifi-
cantly high proportion of CS both fractions were subjected to exhaustive digestion with 
chondroitinase ABC and compositional SAX-HPLC disaccharide analysis was subse-
quently performed. Only minimal digestion by chondroitinase ABC was observed for 
both L. vannamei fractions; evidenced by the low intensity of the HPLC chromatogram at 
232 nm (A1). This could further indicate the presence of rare sulphate modifications on 
GlcA residues as previous reports have shown that such modifications can prohibit cleav-
age by chondroitinase ABC and, where digestion has been reported, the resulting prod-
ucts were not detectable by HPLC analysis, potentially owing to the destruction of the 3-
O-sulphate modification [37–39]. This implies the presence of sulphate modifications 
within F4 and F5 that render the GAG either chain largely resistant to chondroitinase ABC 
digestion, resulting in oligosaccharides, and/or the presence of high levels of 3-O-sul-
phated GlcA residues. Matched chondroitinase ABC digestions of CSC and CSA stand-
ards were also employed as a positive control to confirm enzyme activity (A2). Digestion 
of CSC and CSA generated major disaccharide products bearing 6S or 4S modifications, 
respectively, which were detected at high intensity at 232 nm, indicating that a lack of 
enzymatic activity could not account for the minimal digestion of L. vannamei F4 and F5. 
Figure 5. (A) 1H and (B) 1H-13C HSQC NMR spectra of L. vannamei F4, (C) 1H and (D) 1H-13C HSQC of L. vannamei F5.
Major signals associated with CS and HS are indicated. Spectral integration was performed on the HSQC using labelled
signals. Glucosamine, Glc; galactosamine, Gal; uronic acid, U; iduronic acid, I.
The anomeric region can be used to further distinguish GAG classes, with the reso-
nance of the anomeric carbon of glucosamine occurring downfield to that of galactosamine.
The presence of the signal at 4.5–6/103 ppm and 5.4/100 ppm in the 1H-13C HSQC of
L. vannamei F4 and F5 can be attributed to position 1 of galactosamine and glucosamine,
respectively [35]. By definition, DS is distinguished from CS through the epimerisation
of the GlcA residue to IdoA. The anomeric peak of IdoA is located further downfield
to that of GlcA at 5.0/105 ppm and 4.5–4.7/106 ppm, respectively [35]. A peak can be
observed corresponding to the presence of GlcA, but not IdoA within the 1H -13C HSQC of
L. vannamei F4 and F5 (Figure 5).
Within the 1H-13C HSQC spectrum of L. vannamei F4 several signals can be observed
that can be attributed to the anomeric position of GlcA at 4.45/106–4.48/106.5ppm and
4.65/106.5–4.7/106.5 ppm, whereas for L. vannamei F5, one peak at 4.7/106.5 ppm is
observed (Figure 5). The downfield shift in the 1H dimension has previously been shown
to be indicative of varying levels of 2-and 3-O sulphation of GlcA residue [24,26], thereby
indicating that the CS component of L. vannamei F4 and F5 could potentially harbour
rare sulphation patterns. A low intensity peak corresponding to iduronic acid can be
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observed at 5.2/101 ppm in both L. vannamei F4 and F5, further indicating the presence of
HS/heparin within both fractions. The peak at 3.4/60 ppm is attributable to position 2 of
N-sulphated glucosamine and the intensity of this peak indicates that the HS component
of L. vannamei F4 and F5 is largely N-sulphated (Figure 5).
The peak at ~3.4/75 ppm in the 1H-13C HSQC of L. vannamei F4 and F5 is attributable
to position 2 of GlcA [36], again additional peaks with a slight downfield shift can be
observed possibly indicating the presence of sulphate modifications. Peaks at ~3.8–3.7/
62–61 ppm and ~4.3–4.2/68–67ppm can be attributed G6(OH) and G6(S) of galactosamine
and glucosamine, respectively. Intensities of these signals indicated that both the CS and
HS component of L. vannamei F4 and F5 contain a higher proportion of G6(S) than G6(OH).
2.2.4. Strong Anion-Exchange High Performance Liquid Chromatography Disaccharide
Compositional Analysis
Since NMR spectroscopy revealed that L. vannamei F4 and F5 contained a significantly
high proportion of CS both fractions were subjected to exhaustive digestion with chon-
droitinase ABC and compositional SAX-HPLC disaccharide analysis was subsequently per-
formed. Only minimal digestion by chondroitinase ABC was observed for both L. vannamei
fractions; evidenced by the low intensity of the HPLC chromatogram at 232 nm (A1).
This could further indicate the presence of rare sulphate modifications on GlcA residues
as previous reports have shown that such modifications can prohibit cleavage by chon-
droitinase ABC and, where digestion has been reported, the resulting products were not
detectable by HPLC analysis, potentially owing to the destruction of the 3-O-sulphate
modification [37–39]. This implies the presence of sulphate modifications within F4 and
F5 that render the GAG either chain largely resistant to chondroitinase ABC digestion,
resulting in oligosaccharides, and/or the presence of high levels of 3-O-sulphated GlcA
residues. Matched chondroitinase ABC digestions of CSC and CSA standards were also
employed as a positive control to confirm enzyme activity (A2). Digestion of CSC and
CSA generated major disaccharide products bearing 6S or 4S modifications, respectively,
which were detected at high intensity at 232 nm, indicating that a lack of enzymatic activity
could not account for the minimal digestion of L. vannamei F4 and F5. The detected digest
products of L. vannamei F4 and F5 are presented in Table 1, however, it should be empha-
sised that the composition reported is based only on the digestible material, which likely
forms a small fraction of the sample. Having said this, the CS disaccharide composition
analysis indicated that L. vannamei F4 possess both CSC and CSA units while, L. vannamei
F5 possess CSC and CSE units.
Table 1. Disaccharide composition analysis of L. vannamei F4, F5, CSA and CSC. N.D; not detected.
∆-Disaccharide L. vannamei F4 (%) L. vannamei F5 (%) CSC (%) CSA (%)
∆-UA-GalNAc 18.3 8.8 3.7 2.4
∆-UA-GalNAc(6S) 75.8 43.0 72.0 4.3
∆-UA-GalNAc(4S) 48.6 3.4 18.2 93.2
∆-UA-GalNAc(4S,6S) N. D 44.9 6.0 N. D
Litopenaeus vannamei F4 and F5 were also subjected to exhaustive, enzymatic digestion
with Pedobacter heparinus lyases I, II and III and the digestion products were subject to
SAX-HPLC disaccharide composition analysis by comparing retention times to those of
eight common HS/heparin ∆-disaccharide reference standards [40]. Mammalian heparin
and HS controls were also extensively digested to confirm that enzymatic activity resulted
in the expected digestion products, because non-mammalian GAGs have been previously
reported to resist heparinase digestion [41] (Table 2).
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Table 2. Disaccharide composition analysis of L. vannamei F4, F5, heparin and HS.
∆-Disaccharide L. vannamei F4 (%) L. vannamei F5 (%) Heparin (%) HS (%)
∆-UA-GlcNAc 14.8 9.4 8.5 37.7
∆-UA-GlcNS 9.6 7.6 3.5 17.8
∆-UA-GlcNAc(6S) 3.7 5.7 5.5 12.8
∆-UA(2S)-GlcNAc 1.1 0.8 2.8 0.4
∆-UA-GlcNS(6S) 31.7 47.9 18.2 18.0
∆-UA(2S)-GlcNS 23.7 12.9 7.6 6.0
∆-UA(2S)-GlcNAc(6S) 0.5 0.6 2.5 0.4
∆-UA(2S)-GlcNS(6S) 14.9 15.0 51.4 7.0
The digestion products for both mammalian heparin and HS agreed with previously
published disaccharide profiles [40]. The trisulphated, ∆-UA(2S)-GlcNS(6S) accounts
for the major disaccharide present in heparin at 51.4% in comparison to HS, where this
disaccharide accounts for ~7% of the total chain. As expected, mammalian HS is composed
primarily of di- and mono- sulphated disaccharide standards; ∆-UA-GlcNS (17.8%), ∆-
UA-GlcNAc(6S) (12.8%), ∆-UA-GlcNS(6S) and (18.0%), accounting for ~ 50% of the total
detected disaccharides. This can be attributable to the NA/NS and NS-domains of HS. The
second most prevalent disaccharide present in mammalian heparin was found to be ∆-UA-
GlcNS(6S) (18.2%), as reported [40]. In comparison and as expected, the most prevalent
disaccharide detected in the mammalian HS sample was the unsulphated, ∆-UA-GlcNAc
(37.7%), which forms the primary constituent disaccharide of NA-domains within HS
(Table 2).
The lyase digestion products of L. vannamei F4 and F5 exhibit a more varied sulphation
profile than mammalian heparin and HS. Both L. vannamei F4 and F5 contain a lower
proportion of the tri-sulphated disaccharide, ∆-UA(2S)-GlcNS(6S), when compared to
heparin at ~15%, however, this is approximately double that typically present in mam-
malian HS (Table 1). L. vannamei F4 exhibited a slightly higher proportion of un-sulphated
disaccharides (∆-UA-GlcNAc) when compared to mammalian heparin at 14.8%. This is
substantially lower than typically reported for HS [40,42,43]. In comparison L. vannamei F5
contained approximately the same proportion of ∆-UA-GlcNAc as mammalian heparin
at 9.4%. Furthermore, both fractions contained a low proportion of both the trisulphated
disaccharide, ∆-UA(2S)-GlcNS(6S) and unsulphated disaccharide, ∆-UA-GlcNAc, which
are characteristic of heparin and HS, respectively, indicating that the L. vannamei fractions
contain a heparin-HS like GAG with structural characteristics that are distinct to their
mammalian counterparts.
Both L. vannamei F4 and F5 are comprised primarily of di-sulphated disaccharides
which account for ~56% and 61% of the chain, respectively; the most prevalent disaccharide
being ∆-UA-GlcNS(6S) for both fractions. ∆-UA-GlcNS(6S) is also the most prevalent di-
sulphated disaccharide present in mammalian heparin and HS. L. vannamei F4 and F5 also
contain ~14% mono-sulphated disaccharides of which the majority can be attributed to ∆-
UA-GlcNS in both fractions, however, this disaccharide was more prevalent in L. vannamei
F4 than F5. L. vannamei F5 also contains a higher proportion of the disaccharide ∆-UA-
GlcAc(6S) compared to F4, at 5.7% and 3.7%, respectively. The percentage of mono-
sulphated disaccharides in the L. vannamei fractions, more closely resembled heparin than
HS which contain ~12% and 31%, respectively. The majority of the HS component of the
L. vannamei fractions contain sulphation at position C6 of glucosamine (F4; 51% and F5;
69%) and are N-sulphated (F4; 80% and F5; 83%) rather than N-acetylated. This analysis
was further confirmed by the 1H-13C NMR spectra of L. vannamei F4 and F5 (Figure 5).
2.3. Glycosaminoglycans from Litopenaeus vannamei Inhibit β-Secretase 1
The inhibition of BACE1 by L. vannamei F4 and F5 was determined through the
deployment of the FRET peptide assay based on the APP Swedish mutation, as previously
described by Mycroft-West et al. (2019 and 2020) [9,30]. In accordance with previous reports,
the IC50 of heparin for BACE-1 inhibition was determined to be ~2 µg·mL−1, with maximal
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inhibition being achieved at concentrations greater than 5 µg·mL−1 [9]. Maximal BACE-1
inhibition by L. vannamei F4 and F5 was observed to occur at two-fold the concentration of
heparin (10 µg·mL−1) with an IC50 of ~4.6 and 5.9 µg·mL−1, respectively. Both L. vannamei
fractions therefore, displayed BACE1 inhibitory activity and F4 was the more potent. As
previously reported [9,44] at low concentrations of heparin (1.3–0.3 µg·mL−1) an increase
in BACE1 activity was observed (Figure 6). The extracts obtained from L. vannamei also
promoted BACE1 activity, however this was reduced in comparison to the heparin at all
concentrations tested (Figure 6).
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Figure 6. Inhibition of the human β-secretase, BACE-1. L. vannamei F4 (A) and F5 (B) were assayed
for their ability to inhibit the human BACE-1 cleavage of a quenched fluorogenic peptide based on
the Swedish mutation. Fluorescent emission was monitored for 90 min (λex = 320 nm, λem = 405 nm).
Data are presented as % inhibition calculated from the mean of the substrate only and containing
no inhibitor controls ± SD (n = 3). The IC50 of L. vannamei F4 (A; solid line, filled circles) and F5 (B;
solid line, filled circles) was determined to be 4.61 µg·mL−1 (R2 = 0.97) and 5.93 µg·mL−1 (R2 = 0.93),
respectively. In contrast the IC50 heparin (A and B dashed line, open circles) was ~2.43 µg·mL−1
(R2 = 0.93).
2.4. Glycosaminoglycans from Litopenaeus vannamei Possess Attenuated Anticoagulant Activities
The anticoagulant activity of heparin hampers the repurposing of this clinically ap-
proved drug as a therapeutic for AD. Owing to this, the anticoagulant activities of the
L. vannamei GAG extracts were determined using the prothrombin time (PT) and acti-
vated partial thromboplastin time (aPTT) assays. In comparison to heparin (193 IU.mg−1),
L. vannamei F4 displayed negligible anticoagulant activity by the PT assay, which measures
the extrinsic coagulation pathway, with EC50 = 1276 µg·mL−1 and = 19.53 µg·mL−1, respec-
tively (Figure 7). L. vannamei F5 demonstrated increased activity in the PT assay compared
to F4 at EC50 = 138.80 µg·mL−1 (Figure 8), however, that is still drastically attenuated in
comparison to heparin. Inhibition of the intrinsic coagulation assay was also measured
by the aPTT assay, where F4 displayed >10-fold reduction in activity in comparison to
heparin, at 27.91 µg·mL−1 and 1.66 µg·mL–1, respectively (Figure 7). Again, L. vannamei
F5 displayed increased activity in the aPTT assay in comparison to L. vannamei F4 at
EC50 = 14.60 µg·mL–1, however, the activity of both fractions was negligible compared
to heparin.
Despite the reduced BACE1 inhibitory activity of F4 and F5 in comparison to heparin,
when anticoagulant activity is considered L. vannamei F4 and F5 displayed increased
therapeutic ratios of 6.10, 2.46 and 0.68, respectively (FRET:aPTT; Table 3). L. vannamei F4,
displayed the greatest therapeutic value of the compounds tested, and as a result, was
utilised for further experiments.
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Figure 8. Anticoagulant activity of L. vannamei F5. (A) Activated partial thromboplastin time
(aPTT) and (B) prothrombin time (PT) inhibitory response (mean % response, ± SD, n = 3) for
heparin (open circle, dashed line) and L. vannamei F5 (closed circle, solid line). aPTT: heparin
EC50 = 1.66 µg ×mL–1; L. vannamei F5 EC50 = 14.60 µg·mL–1. PT: heparin EC50 = 19.53 µg·mL–1;
L. vannamei F5 EC50 = 138.80 µg·mL–1.
Table 3. Therapeutic ratio of L. vannamei F4 and F5 compared to heparin. The therapeutic ratio was calculated from the IC50
of BACE1 inhibitory activity measured by FRET:aPTT anticoagulant activity. GAG = glycosaminoglycan, PMIH = porcine
mucosal intestinal heparin, aPTT = activated partial thromboplastin time, PT = prothrombin time.
GAG aPTT (µg·mL−1) PT (µg·mL−1) BACE1 Inhibitory Activity (µg·mL−1) Therapeutic Ratio
PMIH 1.66 19.53 2.43 0.68
L.vannamei (F4) 27.91 1276.00 4.61 6.10
L.vannamei (F5) 14.60 138.80 5.93 2.46
2.5. Glycosaminoglycans from Litopenaeus vannamei Decrease the Thermal Stability of BACE1
Previously, GAGs have been shown to destabilise BACE1; observed by a reduction
in the melting temperature (Tm) of BACE1 in differential scanning fluorimetry (DSF)
measurements. At 50 µg·mL−1, where maximal destabilisation was observed, heparin
induced a ∆Tm of ~10 ◦C. At an equivalent concentration L. vannamei F4 induced ~5 ◦C
reduction in Tm indicating that both fractions destabilised BACE1 in a similar manner to
heparin and other GAGs [9,30]. Destabilisation of BACE1, as measured through DSF, by
heparin and L. vannamei F4 was also found to be dose dependent (Figure 9).
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l l te from fitting the CD spectra against a rep sentative protein library (BeStSel; [45])
in line with the percentage structural composition, predicated by the x-ray crystal structure
of BACE1 at pH 4.0 (PDB: 2ZHS; [9,46]). The CD spectrum of BACE1 alone exhibited
secondary structure composition of 6% helix, 35% antiparallel, 0% parallel, 16% turn, and
43% other, in accordance with previous reports [9]. Circular dichroism spectroscopy was
then performed at 1:4 (w/w) ratio of BACE1 to polysaccharide; the same ratio at which
L. vannamei F4 exhibited maximal inhibition in FRET assays. Under these conditions we
previously reported that heparin and HS-like polysaccharides induce a conformational
change in BACE1 that resulted in increased α-helix and reduced antiparallel β-sheet
content [9]. In agreement with our previous reports, the CD spectra of BACE1 in the
presence of heparin (1:4 w/w; BACE1:heparin) resulted in an increase in α-helix content
(+8%), a reduction in antiparallel β-sheet (−35%). BACE1 in the presences of L. vannamei
F4 (1:4 w/w; BACE1: L. vannamei F4) also exhibited an increase in α-helix content (+2%)
and reduced antiparallel β-sheet (−6%), indicating a common conformational change in
BACE1 upon GAG binding (Figure 10).
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3. Discussion
The extract obtained from L. vannamei was confirmed to be composed of a heteroge-
nous mixture of GAGs, including CS, HS and DS, by NMR spectroscopy. 1H-13C HSQC
NMR revealed that L. vannamei F4 and F5, eluted from DEAE-Sephacel with 0.8 M and 1M
NaCl, respectively were composed primarily of HS, CS and a smaller proportion of DS.
When analysed by agarose gel electrophoresis, both L. vannamei fractions were observed
to contain a major band with a migration distance corresponding to heparin/HS and a
minor band corresponding to mono- and di-sulphated CS. Previous reports have indicated
that CS obtained from L. vannamei, eluted form DEAE-Sephacel at 0.8 and 1M NaCl, also
possessed similar electrophoretic mobility to HS [24,26]. The difference in electrophoretic
mobility of these CS extractions from L. vannamei could be attributed to the presence of
rare sulphate modifications at positions 2 and 3 on the GlcA residue. In support of this,
in the present study 1H-13C HSQC NMR of the L. vannamei fractions revealed a peak at
approximately 4.7/106 ppm, which was indicative of 2 or 3-sulphated GlcA residues in
the aforementioned CS extractions obtained from L. vannamei by Palhares et al. (2019) [24]
and Cavalcante et al. (2018) [26]. The presence of sulphated GlcA residues could therefore
account for the higher proportion of CS within the L. vannamei fractions, when analysed by
NMR spectroscopy, in comparison to ATR-FTIR spectroscopy and agarose electrophore-
sis. In further support of the presence of 2 and/or 3-sulphated GlcA modifications on
the L. vannamei GAG fractions described in this study, digestion by chondroitinase ABC
yielded minimal detectable disaccharide products when analysed by SAX-HPLC. It has
previously been established that sulphate modifications on GlcA residues of chondroitin
sulphate can render disaccharides resistant to chondroitinase ABC digestion [37], and
GlcA-Gal disaccharides bearing 3-O sulphate modifications are largely undetectable by
HPLC analysis [38].
In addition to sulphated GlcA residues, NMR analysis revealed that L. vannamei
F4 and F5 contains primarily Gal6(S). The higher level of sulphation at position 6 of
galactosamine in fraction 4 was also detected through SAX-HPLC disaccharide analysis of
the digested components. In addition to Gal6S, SAX-HPLC disaccharide analysis revealed
the presence of Gal4S (CSA) in L. vannamei F4 and Gal4S,6S (CSE) in L. vannamei F5. This is
in contrast to NMR analysis, which did not detect sulphation at position 4 of galactosamine
in either fraction. As digestion of both L. vannamei by chondroitinase ABC yielded minimal
detectable disaccharide products, the absence of Gal4S in 1H-13C HSQC NMR analysis
may be explained by a low incidence of this modification within the extract. Having said
this, constitutional analysis by both 1H-13C HSQC NMR and SAX-HPLC reveals that the
sulphation pattern of the CS component of the L. vannamei fractions is complex and further
analysis would be required to resolve the fine structure of the CS within this extract.
L. vannamei F4 and F5 possess BACE1 inhibitory activity, albeit at reduced levels in
comparison to heparin, using the previously described FRET-peptide assay. L. vannamei
F4 possesses a slightly increased BACE1 inhibitory activity in comparison to L. vannamei
F5, with IC50 of 4.6 µg·mL–1 and 5.9 µg·mL–1, respectively. Both L. vannamei fractions are
predominantly composed of a mixture of CS and HS. Previously, we have identified a CS
extract from Sardina pilchardus [30] that displayed BACE1 inhibitory activity, therefore it
cannot be assumed that HS is the sole active component of the L. vannamei extract and it is
likely that defined sulphation patterns within CS and HS chains are required for BACE-1
inhibitory activity, as previously described [11,30]. The majority of the HS component of
the L. vannamei fractions contained sulphation at position C6 of glucosamine (F4; 51% and
F5; 69%) and N-sulphation as opposed to N-acetylation (F4; 80% and F5; 83%). Previously
6-O sulphation of heparin has been reported to be important for BACE1 inhibitory activity,
therefore this extract provides further support that 6-O-sulphation of HS/heparin is impor-
tant for BACE1 inhibitory activity [11]. The ability of the L. vannamei extract to promote
proBACE1 at low concentrations was considerably diminished compared to heparin. This
has also been demonstrated for other marine GAGs [8,30], indicating that this source of
GAGs may be more favourable for therapeutic applications against AD.
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As the anticoagulant activity of heparin-based pharmaceuticals hampers the repur-
posing of these clinically approved drugs for the treatment of AD, the effect of L. vannamei
F4 and F5 on the intrinsic, extrinsic and common coagulation pathways was examined.
Both L. vannamei fractions exhibited negligible anticoagulant activities in the aPTT and PT
assays therefore, despite the diminished BACE1 inhibitory activity of L. vannamei F4 and F5
in comparison to heparin, the therapeutic value is greater when off target anticoagulation
activity is taken into account. L. vannamei F4 demonstrated a higher therapeutic value than
both heparin and L. vannamei F5.
To assess whether L. vannamei F4 inhibited BACE1 via a mechanism similar to heparin,
the interaction with BACE1 was examined via CD spectroscopy and DSF. Circular dichro-
ism spectroscopy of BACE1 in the presence of GAGs has previously been shown to induce
conformational changes, in contrast to peptide inhibitors, for which no change in secondary
structure was determined [47]. In addition, DSF measurements have previously identified
a reduction in the melting temperature (Tm) of BACE1 in the presence of GAGs [9,30], again
this is in contrast to other inhibitors for which a stabilising effect has been observed [48].
Here, BACE1 also exhibited a decreased Tm, when measured using DSF, in the presence of
L. vannamei F4 in a concentration dependent manner. The reduction in the Tm of BACE1
in the presence of L. vannamei F4 was two-fold lower than for heparin, comparable to
the IC50 of L. vannamei F4 in FRET-based assays, being double than that of heparin. This
provides further support that a reduction in the Tm of BACE1 in the presence of GAG-like
polysaccharides, when measured using DSF, can infer potential inhibitory activity. The
conformational change of BACE1 in the presence of heparin observed by CD experiments,
has been shown to results in an increase in α-helix content and reduction in antiparallel
β-sheet [9]. This change in secondary structure is in-line with conformational changes
observed between BACE1 in active (pH 4.0) and inactive (pH 7.4) conformations [47]. The
CD spectra of BACE1 in the presence of L. vannamei F4 also exhibited an increase in α-helix
content and reduction in antiparallel β-sheet. This suggests that inhibition of BACE1 by
GAGs occurs via inducing a conformational change, rendering BACE1 inactive, and that
this is distinct from the effects of known peptide inhibitors.
In addition to attenuated anticoagulant activities of non-heparin GAGs, which are
known to possess minimal inhibition of the coagulation cascade (with the exception of
chemically over sulphated CS; [49], further advantages for utilising non-heparin GAGs as
potential therapeutics for AD exist. Notably, CS is widely utilised as a nutraceutical and
is licenced as a treatment for osteoarthritis [50] for which no significant side effects have
been reported [51]. This is in contrast to some heparin pharmaceuticals, in which heparin
induced thrombocytopenia (HIT) is a severe off-target affect. Moreover, non-heparin
GAGs have previously been demonstrated to display favourable pharmacokinetics and
in addition to subcutaneous injection have been shown to be bioavailable through oral
administration [50,51]. This is superior to heparin-like GAGs, which require additional
formulations to enable absorption when administered through oral routes and to peptide
inhibitors that can display unfavourable pharmacokinetic properties [6]. Chondroitin
sulphate, HS and derivatives thereof have also been shown to exert favourable activities
against oxidative stress, tau aggregation, the prevention of Aβ associated apoptosis, and
possess anti-inflammatory properties [51–54], demonstrating the potential of non-heparin
GAGs as a multi-target drug for the treatment of AD, which would be amenable to oral
prophylactic administration.
The use of marine-derived GAGs offers the further advantage of offering increased
structural diversity and being easily extractable from aquaculture waste, making this a
viable, economically and environmentally attractive source for therapeutic exploitation.
4. Methods
4.1. Isolation of Glycosaminoglycans from Litopenaeus vannamei
L. vannamei tissue (3.5 kg; Wm Morrisons, Bradford, UK) was defatted by homogeni-
sation in excess acetone (VWR, Lutterworth, UK) and the mixture was incubated for 24 h
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at room temperature (r.t). Defatted tissue was centrifuged for 10 min at 5670 g and the
remaining acetone allowed to evaporate overnight. The dried tissue was subsequently
digested for 24 h at 60 ◦C with Alcalase (~17 U.kg−1 of dried tissue mass; Novozymes,
Bagsvaerd, Denmark) in PBS, 1M NaCl, pH 8.0. Debris was removed via centrifugation
for 10 min at 5670 g, before addition of Amberlite IRA-900 ion (exchanged into the hy-
droxide counterion form; Sigma-Aldrich, Dorset, UK) into the supernatant. Following
incubation at r.t. for 24 h with agitation, the resin was recovered and washed sequentially
with 10 volumes of dH2O and 1 M NaCl (r.t.). Bound material was eluted by incubating
the resin in 3 M NaCl under agitation for 24 h (r.t). The resin was removed by filtration
prior to precipitation of the crude GAG extract with ice cold methonol (1:1 v/v) at 4 ◦C for
48 h (VWR, Lutterworth, UK). The crude GAG extract was collected via centrifugation at
15,400 g (4◦C) for 1 h, resuspended in dH2O and dialysed for 48 h against dH2O (3.5 kDa
MWCO; Biodesign, Carmel, NY, USA). The solution was filtered (0.2 µm syringe filter) and
lyophilised prior to resuspension in 1 mL of ddH2O (Fisher Scientific, Loughborough, UK).
The crude GAG extract was then fractionated by DEAE-Sephacel chromatography, loading
onto a pre-packed column (10 mm I.D. × 10 cm; GE Healthcare, Buckinghamshire, UK)
at a flow rate of 1 mL ×min−1. Fractions were eluted with a step-wise gradient of NaCl,
with in-line monitoring at 232 nm and 210 nm (not shown) (UV/vis, Cecil Instruments,
Cambridge, UK). Six fractions were collected (F1–6) corresponding to 0, 0.25, 0.5, 0.8, 1
and 2 M NaCl, respectively. Each fraction was dialysed for 48 h against dH2O, prior to
lyophilisation and storage at 4 ◦C.
4.2. Agarose-Based, Gel Electrophoresis
Gel electrophoresis of GAGs (5 µg) was conducted utilising 8 × 8 cm, 1.5 mm thick
gels composed of 0.55% (w/v) agarose in 50 mM 1,3-diaminopropane-acetate buffer, pH
9.0 (VWR, Altrincham, UK). Electrophoresis was performed at 150 V for 30 min in 50 mM
1,3-diaminopropane-acetate buffer using a X-Cell SureLock ™ Mini-Cell Electrophoresis
System (ThermoFisher, Altrincham, UK). Subsequent to electrophoretic separation, gels
were subjected to cetyltrimethylammonium bromide (CTA) precipitation (0.1% w/v) for
4 h and dried overnight. Staining was performed in acetic acid:ethanol:H2O (0.1:5:5 v/v)
solution supplemented with 0.1% (w/v) toludine blue for 1 h and de-stained in the same
solution without the toludine blue dye. Images were acquired using GIMP software (v2.8,
Berkeley, CA, USA) and processed with Image J (v1.51 (100), Madison, QI, USA).
4.3. Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy
Attenuated Total Reflectance Fourier Transform Infrared Spectra were recorded using
10 mg of freeze-dried sample on a Bruker Alpha 1 instrument. An average of 32 scans
over 5 repeats were carried out with a spectral resolution of 2 cm−1 over the range
400–4000 cm−1. Spectral acquisition, background correction and data analysis were per-
formed using Opus software (v8.1, Bruker, UK), an Asus Vivibook Pro (M580VD-EB76,
Taipei, Taiwan) and R Studio (v1.1.463; Boston, MA, USA). Spectral smoothing (Savitzky-
Golay) using a 2nd degree polynomial (21 neighbours) and baseline correction (7th-order
polynomial and normalization between 0–1) were applied. The spectral regions between
2000–2500 cm−1, below 700 cm−1, and above 3600 cm−1 were removed to diminish the
effects of environmental variations (CO2 and H2O regions) prior to the plotting of second
derivatives (Savitzky–Golay algorithm, 2nd order polynomial with 41 neighbours). Prin-
cipal component analysis (PCA) was performed on the normalized and corrected matrix
of intensities, employing singular value decomposition through R studio (mean-centered,
base prcomp function).
4.4. Strong Anion-Exchange High Performance Liquid Chromatography HS/Heparin Discacchaide
Compositional Analysis
L. vannamei samples and a porcine heparin control (50 µg) were subject to exhaustive
bacterial lyase digestion by the sequential addition of recombinant heparinase enzymes (I,
III and II; 2.5 mIU·mg−1; Iduron, Manchester, UK) in 25 mM sodium acetate containing
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5 mM calcium acetate at pH 7.0. Samples were incubated at 37 ◦C for 4 h prior to addition
of all three enzyme and incubation at 37 ◦C, overnight. A ProPac PA-1 analytical column
(4 × 250 mm, Dionex, Loughborough, UK), was pre-equilibrated in HPLC-grade H2O
(1 mL min−1) prior to the injection of the digested samples. The flow was held isocratic in
H2O for 10 min prior to a linear gradient from 0 to 2 M NaCl (HPLC grade; VWR, Lutter-
worth, UK) over 60 min. Detection of eluted ∆-disaccharides was carried out by monitoring
UV absorbance at λ = 232 nm. Retention times were correlated against the 8 common
∆-disaccharide reference standards for heparin according to [40] (Iduron, Manchester, UK).
The ProPac PA-1 column was washed with 2 M NaCl and HPLC-grade H2O prior to use
and between runs.
4.5. Strong Anion-Exchange High Performance Liquid Chromatography Chondrotin Sulphate
Discacchaide Compositional Analysis
L. vannamei samples, chondrotin sulphate A and chondrotin sulphate C (50 µg) were
subject to exhaustive digestion by chondroitin ABCase (Sigma, Dorset, UK) in 50 mM Tris-
HCl containing 60 mM sodium acetate and 0.02% w/v BSA at pH 8. Samples were incubated
at 37 ◦C for 4 h prior to a subsequent addition of further chondroitin ABCase and incuba-
tion at 37 ◦C overnight. A SphereClone analytical column (4.6 × 250 mm, Phenomenex,
Macclesfield UK), was pre-equilibrated in HPLC-grade H2O, pH 3.5 (1 mL·min−1) prior to
the injection of the digested samples. The flow was held isocratic in H2O for 10 min prior
to a linear gradient from 0 to 2 M NaCl, pH 3.5 (HPLC grade; VWR, Lutterworth, UK) over
60 min. Detection of eluted ∆-disaccharides was carried out by monitoring UV absorbance
at λ = 232 nm. Retention times were correlated against the 4 most common ∆-disaccharide
reference standards for CS according to [40] (Iduron, Manchester, UK). The SphereClone
column was washed with 2 M NaCl pH 3.5 and HPLC-grade H2O pH 3.5 prior to use and
between runs.
4.6. Nuclear Magnetic Resonance
L. vannamei samples were lyophilised prior to resuspension in D2O (600 µL; VWR,
Lutterworth, UK); this process was repeated thrice. NMR experiments were conducted
at 298 K using an Avance Neo 800 MHz spectrometer equipped with a 5 mm TXI Probe
800 MHz (Bruker, Coventry UK). In addition to 1-dimensional (1H) spectra, 1H–13C Het-
eronuclear Single-Quantum Correlation (HSQC) 2-dimensional spectra were collected
using standard pulse sequences. Spectra were processed and integrated using TopSpin
software (4.1.0; Bruker, Coventry, UK) and plotted using Mnova (Mestrelab, Santiago de
Compostela, Spain).
4.7. Glycosaminoglycans from Litopenaeus vannamei Inhibit β-Secretase 1
Litopenaeus vannamei F4, F5 and heparin were assayed for inhibitory activity against
tag-free, human BACE1 (ACRO Biosystems, Newark, Delaware, USA), using the fluo-
rescence resonance energy transfer (FRET) assay. Human BACE1 (312.5 ng) and L. van-
namei F4, F5 or heparin were incubated in 50 mM sodium acetate (pH 4.0, 37 ◦C for
10 min), prior to the addition of a quenched, fluorescent peptide substrate (6.25 µM;
MCA-SEVNLDAEFRK(DNP)RR-NH2; Biomatik, Kitchener, ON, Canada) pre-incubated
at 37 ◦C for 10 min in a final well volume of 50 µL. Fluorescent emission was moni-
tored at λexc = 320 nm, λemm = 405 nm, over 90 min using a Tecan Infinite® M200 Pro
multi-well plate reader (Tecan Group Ltd., Zürich, Switzerland) with i-control™ software.
∆RFU.min−1 was calculated through the linear range of the control with no inhibitor, with
normalized percentage inhibition calculated (% ± SD, n = 3) compared to the mean of the
substrate only and no inhibitor controls, prior to the fitting of a four-parameter logistics
model with Prism 7 (GraphPad Software, San Diego, CA, USA).
4.8. Activated Partial Thromboplastin Time
Glycosaminoglycan samples (or control), pooled, normal human plasma (citrated;
Technoclone, Vienna, Austria) and Pathromtin SL reagent (Siemens, Munich, Germany)
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were incubated for 120 s (37 ◦C) prior to the addition of 50 mM CaCl2 (VWR, Lutterworth,
UK; Vtot = 175 uL, 1:2:2:2 v/v). Clot formation times were determined using a Thrombotrak
Solo coagulometer (Axis-Shield, Dundee, UK). An upper maximal of 120 s, representing
100% inhibition of clotting was adopted. Water (0% clot inhibition, representing a nor-
mal aPTT clotting time, of around 37–40 s) and porcine heparin (193 IU.mg−1; Celsus,
Cincinnati, OH, USA) were used as controls. EC50 values were calculated by the fitting of a
sigmoidal dose response curve (GraphPad Prism 7, San Diego, CA, USA).
4.9. Prothrombin Time
Glycosaminoglycan samples (or control) and pooled, normal human plasma (citrated;
Technoclone, Vienna, Austria) were mixed for 60 s (37 ◦C) prior to the addition of Throm-
borel S reagent (Siemens, Munich, Germany; Vtot = 150 uL, 1:1:1 v/v). Clot formation
times were determined using a Thrombotrak Solo coagulometer (Axis-Shield, Dundee, UK)
with an upper maximal of 2 min (representing 100% inhibition of clotting). H2O (0% clot
inhibition, representing a normal PT clotting time of around 13–14 s) and porcine heparin
(193 IU.mg−1; Celsus, OH, USA) were used as controls. EC50 values were calculated by the
fitting of a sigmoidal dose response curve (GraphPad Prism 7, San Diego, CA, USA).
4.10. Differential Scanning Flurimetry
Differential scanning fluorimetry (DSF) was carried out as per the modified method of
Niesen et al. (2007) [55], as described by Uniewicz et al. (2010) [56]. Human BACE1 (1 µg),
20× Sypro Orange and heparin, L. vannamei GAG or dH2O control were assayed by DSF in
50 mM sodium acetate, pH 4.0, in a final well volume of 40 µL using 96-well qPCR plates
(AB Biosystems, Warrington, UK) using an AB Biosystems StepOne plus qPCR machine.
The TAMRA filter was employed using an initial incubation phase of 20 ◦C for of 2 min,
followed by an increase of 0.5 ◦C per 30 s up to a Tmax of 90 ◦C. Data analysis using Prism
7 (GraphPad Software, San Diego, CA, USA) was carried out, plotting the smoothed (19
neighbours, 2nd-order polynomial; Savitzky-Golay) first derivative. The peak (Tm) of the
first derivative was ascertained using MatLab software (R20018a, MathWorks, Cambridge,
UK).
4.11. Circular Dichroism
The circular dichroism (CD) spectra of native human BACE1 (6.12 µM, 30 µL; ACRO
Biosystems, Newark, Delaware, USA) in 50 mM sodium acetate (pH 4.0; VWR, Lutterworth,
UK) was recorded on a J-1500 Jasco CD spectrometer controlled via Spectral Manager II
software and calibrated prior to use against (+)-10-camphorsulfonic acid (1 mg·mL−1). A
0.2 mm pathlength quartz cuvette (Hellma, Plainview, NY, USA) was employed with a scan
speed of 100 nm.min−1 and a 1 nm resolution (180–260 nm). All spectra were the mean of
five independent scans. BACE1 was buffer exchanged prior to spectral acquisition using a
10-kDa centrifugal filter (Sartorius, Goettingen, Germany) at 12,000 g washed three times.
Collected data was further process using GraphPad Prism 7 (smoothed to 9 neighbours,
2nd-order polynomial). The prediction of protein secondary structure was obtained using
the BeStSel analysis server on unsmoothed data [45]. To ensure the CD spectral changes
that were observed when BACE1 was recorded in the presence of each GAG were not an
artefact of the addition of the GAG alone (GAGs are known to possess CD spectra at high
concentrations [57], GAG control spectra were subtracted before analysis. Additionally,
the theoretical, additive CD spectra was verified to differ from the observed CD spectra,
indicating that changes in the CD spectra, compared to that of BACE1 alone, are a result of
a conformational change upon the interaction with the GAG. The conformational change is
thought to occur owing to changes solely in BACE1 secondary structure, as GAG controls
exhibited all but negligible spectra when assayed at the concentration used. All CD data
presented have had the relevant GAG controls subtracted and have been normalized at
260 nm.
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Figure A1. UV-SAX HPLC disaccharide composition analysis was performed on the ABC chon-
droitinase digest of P. vannamei F4 (A) and F5 (B) ([A]232 nm) eluting with a linear gradient of 0–2 M 
NaCl (dashed line), pH 3.5. Eluted Δ-disaccharides were referenced against four common stand-
ards present with CS (light grey dotted line). * Indicates contaminant peaks.  
 
Figure A2. UV-SAX HPLC disaccharide composition analysis was performed on the ABC chon-
droitinase digest of CSA F4 (A) and CSC (B) ([A]232 nm) eluting with a linear gradient of 0–2 M NaCl 
(dashed line), pH 3.5. Eluted Δ-disaccharides were referenced against four common standards 
present with CS (light grey dotted line). * Indicates contaminant peaks. 
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